Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 8—August 2021
Perspective

Comparison of Lyme Disease in the United States and Europe

On This Page
Erythema Migrans and Other Skin Manifestations
Neurologic Manifestations
Lyme Arthritis
Laboratory Diagnosis, Treatment, and Prophylaxis
Lyme Borrelia Co-infections
Conclusions
Cite This Article
Figures
Figure 1
Figure 2
Figure 3
Figure 4
Tables
Table 1
Table 2
Table 3
Podcast
presentation_01 Listen to audio/Podcast
Downloads
Article
RIS [TXT - 2 KB]
Article Metrics
Metric Details
Related Articles
Computerized Systems for Pneumonia Surveillance
Lyme Disease Health-Related Behaviors
B. burgdorferi Among Dogs, North Carolina, USA
More articles on Lyme Disease
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (A.R. Marques); University Medical Centre Ljubljana, Ljubljana, Slovenia (F. Strle); New York Medical College, Valhalla, New York, USA (G.P. Wormser)

Cite This Article

Abstract

Lyme disease, or Lyme borreliosis, is the most common tickborne disease in the United States and Europe. In both locations, Ixodes species ticks transmit the Borrelia burgdorferi sensu lato bacteria species responsible for causing the infection. The diversity of Borrelia species that cause human infection is greater in Europe; the 2 B. burgdorferi s.l. species collectively responsible for most infections in Europe, B. afzelii and B. garinii, are not found in the United States, where most infections are caused by B. burgdorferi sensu stricto. Strain differences seem to explain some of the variation in the clinical manifestations of Lyme disease, which are both minor and substantive, between the United States and Europe. Future studies should attempt to delineate the specific virulence factors of the different species of B. burgdorferi s.l. responsible for these variations in clinical features.

Lyme disease, or Lyme borreliosis, is the most common tickborne disease in both the United States and Europe; an estimated ≈476,000 cases are diagnosed and treated per year in the United States and >200,000 cases per year in western Europe (1–3). The principal tick vector in the United States is Ixodes scapularis, followed by I. pacificus; in Europe, most cases are transmitted by I. ricinus, followed by I. persulcatus ticks (Table 1). The etiologic agent, Borrelia burgdorferi, was discovered in 1982 in the United States. Later, it became recognized that strains of B. burgdorferi in Europe were more heterogenous than strains in North America. B. burgdorferi sensu lato was then classified into 3 main genospecies. The originally discovered genospecies was named B. burgdorferi sensu stricto. The second genospecies was named Borrelia garinii sp. nov., and the third was named Borrelia afzelii sp. nov. Recently, the taxonomy of the family Borreliaceae (and the genus Borrelia) has been revised into 2 main genera, Borrelia and Borreliella (4). The spirochetes that cause relapsing fever retained the genus name Borrelia, and spirochetes that cause Lyme disease have been renamed Borreliella (hereafter referred to as Lyme borrelia). However, these changes have been challenged (5).

Most cases of Lyme disease in the United States occur in the mid-Atlantic, Northeast, and Upper Midwest regions. B. burgdorferi s.s., which also is found in Europe, causes most human infections in the United States (1,2); the newly recognized species B. mayonii (which is not known to exist in Europe) is an infrequent cause of human illness in the Upper Midwest region of the United States (6). The incidence of Lyme disease in Europe is highest in the Scandinavian and Baltic states in northern Europe and in Austria, the Czech Republic, Germany, and Slovenia in central Europe. B. afzelii and B. garinii are the genospecies most frequently detected in I. ricinus and I. persulcatus ticks and cause most cases of Lyme disease in Europe (1,2). Neither genospecies is found in the United States. Transmission of B. burgdorferi s.s. by I. scapularis or by I. pacificus ticks is very infrequent during the first 36 hours after tick attachment; in contrast, transmission of B. afzelii by I. ricinus ticks may occur within 24 hours (Table 1) (7).

Erythema Migrans and Other Skin Manifestations

Figure 1

Erythema migrans skin lesions from patients in Europe (A, B) and the United States (C, D).

Figure 1. Erythema migrans skin lesions from patients in Europe (A, B) and the United States (C, D).

After Lyme borrelia are deposited in the skin by the bite of an infected Ixodes tick, an infection is typically established at that site, which causes the characteristic skin lesion, erythema migrans (Figure 1). Erythema migrans is the most common clinical manifestation of Lyme disease in the United States and Europe, occurring in >80% of patients in both geographic areas (2). Overall, US patients with erythema migrans caused by B. burgdorferi s.s. are less likely than patients in Europe with erythema migrans caused by B. afzelii or B. garinii to remember a tick bite at the site of the lesion (25% vs. 60% for B. afzelii or 64% for B. garinii) but more likely to have concomitant systemic symptoms (69% vs. 38% or 37%), multiple erythema migrans skin lesions (13% vs. 5% for both B. afzelii and B. garinii), and regional lymphadenopathy (29% vs. 8% or 3%) (8–10) (Table 2). Erythema migrans lesions in patients acquiring the infection in the United States have a shorter incubation period from tick bite to lesion development and are less likely to have central clearing at the time of diagnosis (8–10). The frequency of central clearing at least partially depends on the duration of the erythema migrans lesion before the diagnosis, and the duration is on average longer in Europe than in the United States (8–10). In Europe, the percentage of patients with multiple erythema migrans lesions is lower for adult patients than for children (8–11), whereas in the United States, multiple erythema migrans lesions occur with similar frequency in adults and children (8,12–14). Patients infected with B. mayonii, found in the Upper Midwest region of the United States, can exhibit multiple and very small erythema migrans lesions (6).

Figure 2

Southern tick-associated rash illness skin lesions. Adapted from Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases.

Figure 2. Southern tick-associated rash illness skin lesions. Adapted from Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases.

In the United States, an entity referred to as southern tick-associated rash illness (STARI) is associated with a skin lesion very similar to erythema migrans (Figure 2). STARI, however, occurs after the bite of ticks of a different species, Amblyomma americanum, and is not caused by Lyme borrelia. The etiology of STARI has not been determined. A. americanum ticks are most frequently found in the southeastern and south-central United States, but their range is spreading to geographic areas where I. scapularis tick bites are common (15). The potential for diagnostic confusion clearly exists in areas such as Long Island, New York, where both tick species coexist. STARI does not occur in Europe, presumably because A. americanum ticks are not found in that geographic area. Available, but limited, data suggest that STARI can be distinguished from erythema migrans on the basis of different serum metabolic profiles (16).

Figure 3

A) Borrelial lymphocytoma on nipple, showing local swelling and a remnant of erythema migrans on chest; at the time of diagnosis, the lesions had been noticed for 6 weeks. B) Acrodermatitis chronica atrophicans involving the right hand, showing red-purple discoloration, swelling, and skin atrophy; at the time of diagnosis, the lesions had been noticed for ≈2.5 years.

Figure 3. A) Borrelial lymphocytoma on nipple, showing local swelling and a remnant of erythema migrans on chest; at the time of diagnosis, the lesions had been noticed for 6 weeks. B)...

Two clinical manifestations of Lyme disease involving the skin occur exclusively in infections acquired in Europe: borrelial lymphocytoma and acrodermatitis chronica atrophicans (ACA) (Figure 3). Borrelial lymphocytoma appears as a small area of skin induration that slowly enlarges to a solitary bluish-red nodule or plaque with a diameter of up to a few centimeters and is predominantly located on the ear lobe in children and on the breast in adults. It usually develops at the site of a tick bite and is often accompanied with an erythema migrans lesion (17). ACA is a late cutaneous manifestation of Lyme disease located primarily on the extensor parts of the distal extremities. It starts with reddish-blue discoloration and swelling of the skin (an inflammatory phase), which slowly enlarges and, if untreated, is followed by atrophic changes several months to years later. For some patients, ACA was known to have been preceded by an earlier manifestation of Lyme disease, such as erythema migrans (18). The apparent explanation for the absence of these manifestations in the United States is that these skin infections are principally caused by B. afzelii (Table 3).

Neurologic Manifestations

The typical presentation of early Lyme neuroborreliosis is cranial nerve palsy, particularly facial nerve palsy, as well as lymphocytic meningitis and painful radiculitis. In the United States, the most common manifestation of early Lyme neuroborreliosis is facial palsy. Most cases of early Lyme neuroborreliosis in Europe are caused by B. garinii and B. bavariensis; in adult patients, painful meningoradiculitis is most common (19,20). In a study of 194 adult patients with Lyme neuroborreliosis in Denmark during 2015–2017, radicular pain affected 70% of the patients and facial nerve palsy 43%; intrathecal production of IgG or IgM against Lyme borrelia was found in 87% (21). Similar results were found in a retrospective series of 431 Lyme neuroborreliosis patients in Denmark, which included 126 children. Radicular pain (in 66%) and facial nerve palsy (in 41%) were the predominant symptoms; 84.5% of patients had evidence of intrathecal antibody production against Lyme borrelia (22). Although there are no comparable studies from the United States, it seems that adult US patients with early Lyme neuroborreliosis less frequently have severe radicular pain (23) (Table 3). Newer studies addressing Lyme neuroborreliosis in the United States would be a welcome addition for providing additional data on the frequency of particular symptoms and also on clarifying the frequency of intrathecal antibody production to B. burgdorferi s.s. at the time of symptom onset.

Late Lyme neuroborreliosis with encephalitis, myelitis, or encephalomyelitis has been reported in Europe but is very rare in the United States (24). On the other hand, 2 neurologic manifestations that have been reported to occur in the United States are now regarded as controversial. The first is Lyme encephalopathy, a poorly defined entity, which occurs in the absence of cerebrospinal fluid pleocytosis, intrathecal production of antiborrelial antibody, or direct microbiologic evidence of B. burgdorferi s.s. infection in the central nervous system. Symptoms include memory and concentration complaints. A now-recognized source of confusion with regard to this entity is that some patients with posttreatment Lyme disease syndrome in the United States report cognitive difficulties, and a subset of these patients have abnormal neurocognitive test results (25,26). Adding to the controversy, however, is the question of what constitutes dysfunction on such testing and the clinical significance of the test results (27).

The second controversial neurologic manifestation in the United States is a chronic distal symmetric sensory neuropathy. In Europe, distal axonal neuropathy in the context of Lyme disease is exclusively associated with ACA. In patients with ACA, the neuropathy is predominantly sensory, most often in the involved skin areas (28). Case series in adult patients in the United States reported a similar neuropathy but without evidence of ACA (29,30). The distribution of neurologic deficits, which is predominantly sensory, is distal and typically symmetric, but it can be asymmetric. The neuropathy is primarily axonal and thought to be a mononeuropathy multiplex, which can be confluent (24). Cerebrospinal fluid examination is usually unremarkable. Major concerns have been raised as to whether this entity has been appropriately validated as a manifestation of B. burgdorferi s.s. infection in the United States (31).

Overall, several factors have probably contributed to the belief that cognitive complaints or a chronic distal symmetric sensory peripheral neuropathy was attributable to Lyme disease in the United States (31). These factors include the use of diagnostic testing that is no longer considered valid, failure to appreciate that background seropositivity for antibodies to B. burgdorferi s.s. exists, and failure to include matched controls to determine if an association with cognitive complaints or peripheral neuropathy with a positive diagnostic assay for Lyme disease is higher than expected.

Lyme Arthritis

Lyme arthritis will develop in ≈60% of US patients with untreated erythema migrans over a 2-year period (32) and is said to comprise 28% of Lyme disease cases reported to the US Centers for Disease Control and Prevention that have data on symptoms available (33). Lyme arthritis seems to be less frequent in Europe (34,35), and for untreated patients in Europe, the interval between onset of erythema migrans and development of Lyme arthritis may be shorter (1). Of note, B. burgdorferi s.s. was the most prevalent species of Lyme borrelia found in synovial fluid in a study of patients with Lyme arthritis in Europe (36). An acute manifestation of Lyme arthritis in children in the United States can mimic septic arthritis; this manifestation, however, does not seem to occur in children in Europe with Lyme arthritis (37).

With regard to demographics, Lyme disease in the United States is more common in male patients (56% of the patients reported during 2001–2018 were male) (38). Indeed, no clinical manifestation has been associated with a female predominance in the United States, whereas in Europe, most cases of erythema migrans and ACA occur in women (39,40). Many studies (but not all) demonstrated a male predominance for Lyme neuroborreliosis and Lyme arthritis (22,35,36,41).

Laboratory Diagnosis, Treatment, and Prophylaxis

Figure 4

Standard 2-tier and modified 2-tier algorithms for serodiagnosis of Lyme disease. The US Centers for Disease Control and Prevention recommended a standard 2-tier algorithm (A) and the modified 2-tier algorithm (B). *For patients with signs or symptoms consistent with Lyme disease for <30 days, the provider may treat and follow up with a convalescent-phase serum sample. Patients with erythema migrans should receive treatment on the basis of the clinical diagnosis. WB, Western blot.

Figure 4. Standard 2-tier and modified 2-tier algorithms for serodiagnosis of Lyme disease. The US Centers for Disease Control and Prevention recommended a standard 2-tier algorithm (A) and the modified 2-tier algorithm...

In the United States and Europe, most laboratory tests performed to diagnose Lyme disease are based on detecting serum antibodies to Lyme borrelia. Because Lyme disease in Europe is caused by a more diverse group of Lyme borrelia, criteria for test interpretation were more challenging to standardize than in the United States. In the United States, the Centers for Disease Control and Prevention has recommended the standard 2-tier algorithm since 1995. This approach typically uses a sensitive enzyme immunoassay (EIA) as the initial step. A negative result requires no further testing. A positive or equivocal result is followed by supplemental testing using separate IgM and IgG immunoblots as the second-tier assay. The interpretation of immunoblot results uses standardized criteria (at least 2 of 3 signature bands for a positive IgM immunoblot and 5 of 10 signature bands for a positive IgG immunoblot). Results from the IgM immunoblot are only relevant when the duration of the illness is <30 days. Of note, testing performed in Europe is more likely to have positive results for patients who acquired Lyme disease in the United States than is testing performed in the United States to diagnose infection acquired in Europe (42). Recently, a 2-EIA approach has been approved as an alternative (or modified) 2-tier testing strategy (Figure 4). This new approach has higher sensitivity in early disease, similar specificity (43), greater ability for automation, and offers objective, quantitative values that leads to less variability in interpretation of the result. Also, the 2-EIA approach can be used in the United States and Europe. Moreover, it opens the door for a possible point-of-care test, a development that would be particularly helpful for patients with facial palsy, carditis, and pediatric patients with Lyme arthritis when septic arthritis is part of the differential diagnosis. A disadvantage is that the 2-EIA approach does not establish the extent of IgG seropositivity, which is essential knowledge for diagnosing late Lyme disease.

Recommendations for treating of Lyme disease are generally very similar in guidelines for the United States and Europe. One difference is that phenoxymethylpenicillin (penicillin V) is recommended for treatment of erythema migrans and borrelial lymphocytoma by some of the guidelines in Europe but is not part of the treatment recommendations in the United States (1,44,45). Another difference is the recommendation by some authorities in Europe to use intravenous ceftriaxone to treat erythema migrans, as well as other manifestations of Lyme disease, in pregnant women; whereas in the United States, antimicrobial drug treatment of Lyme disease for pregnant women is the same as that for nonpregnant patients, except that doxycycline is not recommended for pregnant women (1,44,46). Postexposure antimicrobial prophylaxis with a single 200-mg dose of doxycycline has been shown to reduce the risk for Lyme disease after an I. scapularis tick bite and is recommended for consideration for tick bite prophylaxis in the United States (44). A recently published study conducted in Europe has also shown that a single 200-mg dose doxycycline successfully prevented Lyme disease after a tick bite (47). To what extent doxycycline will be used in Europe after a tick bite is unknown; the standard of care has been observation (1).

Lyme Borrelia Co-infections

Ixodes ticks can carry multiple pathogens, and a single tick bite may result in transmission of >2 infectious agents. Pathogens potentially transmitted by I. scapularis ticks to humans include B. burgdorferi s.s., B. mayonii, B. miyamotoi, Anaplasma phagocytophilum, Babesia microti, Ehrlichia muris eauclairensis, and the deer tick virus subtype of Powassan virus (48). The frequency of co-infections depends on the prevalence of the infectious agents in ticks, which will vary in different geographic areas. In the United States, A. phagocytophilum and B. microti are the most frequent co-infections in patients with Lyme disease (49). In the northeastern United States, ≈11% of patients infected with B. miyamotoi, a relapsing fever spirochete, are co-infected with B. burgdorferi s.s.; of note, B. miyamotoi infections per se can cause positive results on first-tier tests for Lyme disease, potentially leading to diagnostic confusion. Encephalitis caused by deer tick virus is relatively rare, but cases may be increasing. In Europe, in addition to Lyme borrelia, I. ricinus ticks can transmit tick-borne encephalitis virus, A. phagocytophilum, species of the bacterial genus Rickettsia, B. miyamotoi, and Babesia protozoans. Tick-borne encephalitis virus is well recognized as a cause of co-infection in patients with Lyme disease in Europe (50). More data are needed on the frequency of co-infections in both the United States and Europe.

Conclusions

Lyme disease is common in many areas of the United States and Europe and may have a variety of clinical manifestations. The duration of infection and the species of Lyme borrelia causing the infection can affect the clinical features of Lyme disease. In the United States, patients with erythema migrans more often have concomitant systemic symptoms than do patients in Europe. In Europe, Lyme arthritis is associated with B. burgdorferi s.s. and Lyme neuroborreliosis with B. garinii. Certain cutaneous manifestations of Lyme disease in Europe do not occur at all in the United States. It will be valuable to delineate the specific virulence factors of the different species of Lyme borrelia that contribute to these clinical differences.

Dr. Marques is chief of the Lyme Disease Studies Unit, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. Her primary research interest is clinical research on Lyme disease and other tickborne illnesses.

Top

Acknowledgments

Funding for this study was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

A.R.M. has a patent US 8,926,989 issued and is an unpaid scientific advisor to the Global Lyme Alliance and to the American Lyme Disease Foundation. F.S. served on the scientific advisory board for Roche on Lyme disease serologic diagnostics, on the scientific advisory board for Pfizer on Lyme disease vaccine, received research support from the Slovenian Research Agency (grant nos. P3-0296, J3-1744, and J3-8195), and is an unpaid member of the steering committee of the ESCMID Study Group on Lyme Borreliosis/ ESGBOR. G.P.W. received research grants from the Institute for Systems Biology and Pfizer, Inc. He owns equity in Abbott/AbbVie, has been an expert witness in malpractice cases involving Lyme disease, and is an unpaid board member of the American Lyme Disease Foundation.

Top

References

  1. Stanek  G, Strle  F. Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev. 2018;42:233–58. DOIPubMedGoogle Scholar
  2. Steere  AC, Strle  F, Wormser  GP, Hu  LT, Branda  JA, Hovius  JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. DOIPubMedGoogle Scholar
  3. Kugeler  KJ, Schwartz  AM, Delorey  MJ, Mead  PS, Hinckley  AF. Estimating the frequency of lyme disease diagnoses, United States, 2010–2018. Emerg Infect Dis. 2021;27:616–9. DOIPubMedGoogle Scholar
  4. Barbour  AG, Gupta  RS. The Family Borreliaceae (Spirochaetales), a diverse group in two genera of tick-borne spirochetes of mammals, birds, and reptiles. J Med Entomol. 2021:tjab055.
  5. Margos  G, Castillo-Ramirez  S, Cutler  S, Dessau  RB, Eikeland  R, Estrada-Peña  A, et al. Rejection of the name Borreliella and all proposed species comb. nov. placed therein. Int J Syst Evol Microbiol. 2020;70:3577–81. DOIPubMedGoogle Scholar
  6. Pritt  BS, Mead  PS, Johnson  DKH, Neitzel  DF, Respicio-Kingry  LB, Davis  JP, et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. Lancet Infect Dis. 2016;16:556–64. DOIPubMedGoogle Scholar
  7. Eisen  L. Pathogen transmission in relation to duration of attachment by Ixodes scapularis ticks. Ticks Tick Borne Dis. 2018;9:535–42. DOIPubMedGoogle Scholar
  8. Strle  F, Nadelman  RB, Cimperman  J, Nowakowski  J, Picken  RN, Schwartz  I, et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med. 1999;130:32–6. DOIPubMedGoogle Scholar
  9. Strle  F, Ružić-Sabljić  E, Logar  M, Maraspin  V, Lotrič-Furlan  S, Cimperman  J, et al. Comparison of erythema migrans caused by Borrelia burgdorferi and Borrelia garinii. Vector Borne Zoonotic Dis. 2011;11:1253–8. DOIPubMedGoogle Scholar
  10. Logar  M, Ruzić-Sabljić  E, Maraspin  V, Lotric-Furlan  S, Cimperman  J, Jurca  T, et al. Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. Infection. 2004;32:15–9. DOIPubMedGoogle Scholar
  11. Arnez  M, Pleterski-Rigler  D, Luznik-Bufon  T, Ruzic-Sabljić  E, Strle  F. Solitary and multiple erythema migrans in children: comparison of demographic, clinical and laboratory findings. Infection. 2003;31:404–9. DOIPubMedGoogle Scholar
  12. Wormser  GP, Ramanathan  R, Nowakowski  J, McKenna  D, Holmgren  D, Visintainer  P, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:697–704. DOIPubMedGoogle Scholar
  13. Eppes  SC, Childs  JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics. 2002;109:1173–7. DOIPubMedGoogle Scholar
  14. Gerber  MA, Shapiro  ED, Burke  GS, Parcells  VJ, Bell  GL; Pediatric Lyme Disease Study Group. Lyme disease in children in southeastern Connecticut. N Engl J Med. 1996;335:1270–4. DOIPubMedGoogle Scholar
  15. Raghavan  RK, Peterson  AT, Cobos  ME, Ganta  R, Foley  D. Current and future distribution of the lone star tick, Amblyomma americanum (L.) (Acari: Ixodidae) in North America. PLoS One. 2019;14:e0209082. DOIPubMedGoogle Scholar
  16. Molins  CR, Ashton  LV, Wormser  GP, Andre  BG, Hess  AM, Delorey  MJ, et al. Metabolic differentiation of early Lyme disease from southern tick-associated rash illness (STARI). Sci Transl Med. 2017;9:eaal2717. DOIPubMedGoogle Scholar
  17. Maraspin  V, Nahtigal Klevišar  M, Ružić-Sabljić  E, Lusa  L, Strle  F. Borrelial lymphocytoma in adult patients. Clin Infect Dis. 2016;63:914–21. DOIPubMedGoogle Scholar
  18. Ogrinc  K, Maraspin  V, Lusa  L, Cerar Kišek  T, Ružić-Sabljić  E, Strle  F. Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients. J Intern Med. 2021;joim.13266; Epub ahead of print. DOIPubMedGoogle Scholar
  19. Coipan  EC, Jahfari  S, Fonville  M, Oei  GA, Spanjaard  L, Takumi  K, et al. Imbalanced presence of Borrelia burgdorferi s.l. multilocus sequence types in clinical manifestations of Lyme borreliosis. Infect Genet Evol. 2016;42:66–76. DOIPubMedGoogle Scholar
  20. Ogrinc  K, Lusa  L, Lotrič-Furlan  S, Bogovič  P, Stupica  D, Cerar  T, et al. Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings. Clin Infect Dis. 2016;63:346–53. DOIPubMedGoogle Scholar
  21. Nordberg  CL, Bodilsen  J, Knudtzen  FC, Storgaard  M, Brandt  C, Wiese  L, et al.; DASGIB study group. Lyme neuroborreliosis in adults: A nationwide prospective cohort study. Ticks Tick Borne Dis. 2020;11:101411. DOIPubMedGoogle Scholar
  22. Knudtzen  FC, Andersen  NS, Jensen  TG, Skarphédinsson  S. Characteristics and clinical outcome of Lyme neuroborreliosis in a high endemic area, 1995–2014: a retrospective cohort study in Denmark. Clin Infect Dis. 2017;65:1489–95. DOIPubMedGoogle Scholar
  23. Pachner  AR, Steere  AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology. 1985;35:47–53. DOIPubMedGoogle Scholar
  24. Halperin  JJ. Diagnosis and management of Lyme neuroborreliosis. Expert Rev Anti Infect Ther. 2018;16:5–11. DOIPubMedGoogle Scholar
  25. Klempner  MS, Hu  LT, Evans  J, Schmid  CH, Johnson  GM, Trevino  RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85–92. DOIPubMedGoogle Scholar
  26. Krupp  LB, Hyman  LG, Grimson  R, Coyle  PK, Melville  P, Ahnn  S, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60:1923–30. DOIPubMedGoogle Scholar
  27. Binder  LM, Iverson  GL, Brooks  BL. To err is human: “abnormal” neuropsychological scores and variability are common in healthy adults. Arch Clin Neuropsychol. 2009;24:31–46. DOIPubMedGoogle Scholar
  28. Kindstrand  E, Nilsson  BY, Hovmark  A, Pirskanen  R, Asbrink  E. Peripheral neuropathy in acrodermatitis chronica atrophicans - a late Borrelia manifestation. Acta Neurol Scand. 1997;95:338–45. DOIPubMedGoogle Scholar
  29. Logigian  EL, Steere  AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology. 1992;42:303–11. DOIPubMedGoogle Scholar
  30. Halperin  JJ, Little  BW, Coyle  PK, Dattwyler  RJ. Lyme disease: cause of a treatable peripheral neuropathy. Neurology. 1987;37:1700–6. DOIPubMedGoogle Scholar
  31. Wormser  GP, Strle  F, Shapiro  ED, Dattwyler  RJ, Auwaerter  PG. A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. Diagn Microbiol Infect Dis. 2017;87:163–7. DOIPubMedGoogle Scholar
  32. Steere  AC, Malawista  SE, Snydman  DR, Shope  RE, Andiman  WA, Ross  MR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum. 1977;20:7–17. DOIPubMedGoogle Scholar
  33. Centers for Disease Control and Prevention. Lyme disease charts and figures: historical data [cited 2020 Nov 15]. https://www.cdc.gov/lyme/stats/graphs.html
  34. Enkelmann  J, Böhmer  M, Fingerle  V, Siffczyk  C, Werber  D, Littmann  M, et al. Incidence of notified Lyme borreliosis in Germany, 2013-2017. Sci Rep. 2018;8:14976. DOIPubMedGoogle Scholar
  35. Strle  F, Wormser  GP, Mead  P, Dhaduvai  K, Longo  MV, Adenikinju  O, et al. Gender disparity between cutaneous and non-cutaneous manifestations of Lyme borreliosis. PLoS One. 2013;8:e64110. DOIPubMedGoogle Scholar
  36. Grillon  A, Scherlinger  M, Boyer  PH, De Martino  S, Perdriger  A, Blasquez  A, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum. 2019;48:1105–12. DOIPubMedGoogle Scholar
  37. Huppertz  HI, Karch  H, Suschke  HJ, Döring  E, Ganser  G, Thon  A, et al.; The Pediatric Rheumatology Collaborative Group. Lyme arthritis in European children and adolescents. Arthritis Rheum. 1995;38:361–8. DOIPubMedGoogle Scholar
  38. Centers for Disease Control and Prevention. Lyme disease charts and figures: most recent year [cited 2020 Nov 15]. https://www.cdc.gov/lyme/datasurveillance/charts-figures-recent.html
  39. Sajanti  E, Virtanen  M, Helve  O, Kuusi  M, Lyytikäinen  O, Hytönen  J, et al. Lyme Borreliosis in Finland, 1995-2014. Emerg Infect Dis. 2017;23:1282–8. DOIPubMedGoogle Scholar
  40. Bennet  L, Stjernberg  L, Berglund  J. Effect of gender on clinical and epidemiologic features of Lyme borreliosis. Vector Borne Zoonotic Dis. 2007;7:34–41. DOIPubMedGoogle Scholar
  41. Rojko  T, Bogovič  P, Lotrič-Furlan  S, Ogrinc  K, Cerar-Kišek  T, Glinšek Biškup  U, et al. Borrelia burgdorferi sensu lato infection in patients with peripheral facial palsy. Ticks Tick Borne Dis. 2019;10:398–406. DOIPubMedGoogle Scholar
  42. Wormser  GP, Tang  AT, Schimmoeller  NR, Bittker  S, Cooper  D, Visintainer  P, et al. Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa. Med Microbiol Immunol (Berl). 2014;203:65–71. DOIPubMedGoogle Scholar
  43. Marques  AR. Revisiting the Lyme disease serodiagnostic algorithm: the momentum gathers. J Clin Microbiol. 2018;56:e00749–18. DOIPubMedGoogle Scholar
  44. Lantos  PM, Rumbaugh  J, Bockenstedt  LK, Falck-Ytter  YT, Aguero-Rosenfeld  ME, Auwaerter  PG, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72:1–8.PubMedGoogle Scholar
  45. Wormser  GP, Strle  F. Evaluation of the role of oral penicillin for treating Lyme disease patients with erythema migrans in the United States. Diagn Microbiol Infect Dis. 2020;97:115071. DOIPubMedGoogle Scholar
  46. Maraspin  V, Lusa  L, Blejec  T, Ružić-Sabljić  E, Pohar Perme  M, Strle  F. Course and outcome of erythema migrans in pregnant women. J Clin Med. 2020;9:E2364. DOIPubMedGoogle Scholar
  47. Harms  MG, Hofhuis  A, Sprong  H, Bennema  SC, Ferreira  JA, Fonville  M, et al. A single dose of doxycycline after an ixodes ricinus tick bite to prevent Lyme borreliosis: An open-label randomized controlled trial. J Infect. 2021;82:98–104. DOIPubMedGoogle Scholar
  48. Nelder  MP, Russell  CB, Sheehan  NJ, Sander  B, Moore  S, Li  Y, et al. Human pathogens associated with the blacklegged tick Ixodes scapularis: a systematic review. Parasit Vectors. 2016;9:265. DOIPubMedGoogle Scholar
  49. Centers for Disease Control and Prevention. Nationally notifiable infectious diseases and conditions, United States: annual tables. Annual data for 2018. Tables 1, 2c, 2e [cited 2020 Nov 15]. https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp?mmwr_year=2018
  50. Velušček  M, Blagus  R, Cerar Kišek  T, Ružić-Sabljić  E, Avšič-Županc  T, F Bajrović  F, et al. Antibiotic use and long-term outcome in patients with tick-borne encephalitis and co-infection with Borrelia Burgdorferi sensu lato in central Europe. A retrospective cohort study. J Clin Med. 2019;8:E1740. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Cite This Article

DOI: 10.3201/eid2708.204763

Original Publication Date: July 14, 2021

Table of Contents – Volume 27, Number 8—August 2021

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Adriana Marques. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10/12C118 10 Center Dr, Bethesda, MD 20892, USA

Send To

10000 character(s) remaining.

Top

Page created: June 21, 2021
Page updated: July 18, 2021
Page reviewed: July 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external